Betahistine, a partial inverse H3 histamine receptor agonist, induced significant weight loss with minimal adverse events in women under 50 years of age (Barak et al. 2008) and in animals with obesity after olanzapine treatment (Lian et al. 2014). This evidence concerns the gene HRH3 and Obesity.